文献速递心境障碍

氯胺酮对难治性抑郁患者信念更新偏倚的早期效应评估

Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

这项观察性病例对照研究纳入26例难治性抑郁患者和30名健康对照,采用混合效应设计比较单次氯胺酮输注前后信念更新任务表现。结果显示患者在接受单次氯胺酮后对好消息的信念更新多于坏消息,该效应与不对称学习率相关,并部分中介早期抗抑郁反应。

要点

  • 难治性抑郁患者单次氯胺酮后对好消息的信念更新多于坏消息,与健康对照存在显著组×时间×效价交互。
  • 计算建模显示氯胺酮后好消息学习率0.51高于坏消息学习率0.36,t25=3.8,P<.001。
  • 不对称学习率部分中介早期抗抑郁反应(path a*b: β=-1.00,P=.04)。

核心结论

  • 氯胺酮可改变难治性抑郁患者的信念更新偏倚,使其对好消息的更新多于坏消息,该认知效应与早期抗抑郁反应部分相关。

研究设计与样本

  • 观察性病例对照协议,采用混合效应设计,将2组按2个测试时间点嵌套,观察者非盲。
  • 纳入26例难治性抑郁患者和30名健康对照,年龄34至68岁,共56人,29人(52%)为男性,平均(SEM)年龄52.3(1.2)岁。
  • 患者需符合重性抑郁障碍或双相抑郁诊断,MADRS评分大于20,Maudsley分期方法评分大于7,且至少2种既往抗抑郁药试验无效。
  • 患者于单次氯胺酮输注前24小时、输注后4小时及首次输注后1周第三次输注后4小时观察;健康对照间隔1周观察两次,无氯胺酮暴露。

主要发现

  • 显著的组×测试时间点×消息效价交互显示,难治性抑郁患者在单次氯胺酮输注后对好消息的信念更新多于坏消息(控制年龄和教育:β=-0.91;95%CI,-1.58至-0.24;t216=-2.67;P=.008),且该效应大于对照。
  • 计算建模显示该效应与氯胺酮治疗后不对称学习率相关:好消息学习率0.51(SEM,0.04),坏消息学习率0.36(SEM,0.03),t25=3.8,P<.001。
  • 不对称学习率部分中介早期抗抑郁反应(path a*b:β=-1.00(SEM,0.66);t26=-1.53;z=-1.98;P=.04)。

关键数值与推荐

  • 难治性抑郁患者入组标准:MADRS评分大于20,Maudsley分期方法评分大于7,至少2种既往抗抑郁药试验无效。
  • 排除标准:任何其他精神、神经或神经外科合并症,物质使用或成瘾障碍,以及娱乐性氯胺酮使用。

临床怎么用

  • 这些发现为氯胺酮在难治性抑郁患者中的作用提供了认知机制的新见解,对心境障碍个体的增强心理治疗具有前景。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical research has shown that persistent negative beliefs maintain depression and that subanesthetic ketamine infusions induce rapid antidepressant responses. OBJECTIVE: To evaluate whether ketamine alters belief updating and how such cognitive effects are associated with the clinical effects of ketamine. DESIGN, SETTING, AND PARTICIPANTS: This study used an observational case-control protocol with a mixed-effects design that nested 2 groups by 2 testing time points. Observers were not blinded. Patients with treatment-resistant depression (TRD) and healthy volunteer participants aged 34 to 68 years were included. Patients with TRD were diagnosed with major depressive disorder or bipolar depression, had a Montgomery-Åsberg Depression Rating Scale score greater than 20, a Maudsley Staging Method score greater than 7, and failed to respond to at least 2 prior antidepressant trials. Exclusion criteria were any other psychiatric, neurological, or neurosurgical comorbidities, substance use or addictive disorders, and recreational ketamine consumption. Data were collected from January to February 2019 and from May to December 2019, and data were analyzed from January 2020 to July 2021. EXPOSURES: Patients with TRD were observed 24 hours before single ketamine infusion, 4 hours after the infusion, and 4 hours after the third infusion, which was 1 week after the first infusion. Healthy control participants were observed twice 1 week apart without ketamine exposure. MAIN OUTCOMES AND MEASURES: Montgomery-Åsberg Depression Rating Scale score and belief updating after belief updating when patients received good news and bad news measured by a cognitive belief-updating task and mathematically formalized by a computational reinforcement learning model. RESULTS: Of 56 included participants, 29 (52%) were male, and the mean (SEM) age was 52.3 (1.2) years. A total of 26 patients with TRD and 30 control participants were included. A significant group × testing time point × news valence interaction showed that patients with TRD updated their beliefs more after good than bad news following a single ketamine infusion (controlled for age and education: β = -0.91; 95% CI, -1.58 to -0.24; t216 = -2.67; P = .008) than controls. Computational modeling showed that this effect was associated with asymmetrical learning rates (LRs) after ketamine treatment (good news LRs after ketamine, 0.51 [SEM, 0.04]; bad news LRs after ketamine 0.36 [SEM, 0.03], t25 = 3.8; P < .001) and partially mediated early antidepressant responses (path a*b: β = -1.00 [SEM, 0.66]; t26 = -1.53; z = -1.98; P = .04). CONCLUSIONS AND RELEVANCE: These findings provide novel insights into the cognitive mechanisms of the action of ketamine in patients with TRD, with promising perspectives for augmented psychotherapy for individuals with mood disorders.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bottemanne H, Morlaas O, Claret A, et al. Evaluation of Early Ketamine Effects on Belief-Updating Biases in Patients With Treatment-Resistant Depression. JAMA Psychiatry. 2022. PMID: 36169969. doi:10.1001/jamapsychiatry.2022.2996

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。